Filtered By:
Drug: Vytorin
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 235 results found since Jan 2013.
The Projected Impact of Population-Wide Achievement of LDL Cholesterol & lt;70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD
ConclusionA substantial number of recurrent ASCVD events could be averted over 10 years if all US adults with ASCVD achieved, and maintained, an LDL-C<70 mg/dL.
Source: Cardiovascular Drugs and Therapy - October 2, 2021 Category: Cardiology Source Type: research
Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study
ConclusionsPatients undergoing a coronary revascularization procedure who received moderate-intensity statins plus ezetimibe showed similar rates of major adverse cardiovascular events as patients who received high-intensity statins.
Source: Cardiovascular Drugs and Therapy - September 17, 2021 Category: Cardiology Source Type: research
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
AbstractPatients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the goal of lowering the Lp(a) level in patients who have increased risk. The American College of Cardiology (ACC) has provided guidelines on how to use traditional lipid profiles to assess the risk of atherosclerotic cardiovascular disease (ASCVD); however, even with the emergence of statin add-on therapies such as ezetimibe and proprotein convert...
Source: American Journal of Cardiovascular Drugs - September 7, 2021 Category: Cardiology Source Type: research
Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention
Proprotein convertase subtilisin/kexin type 9 (PCSK9) interacts with the low-density lipoprotein (LDL) receptor and, by enhancing its degradation, has a pivotal role in the regulation of cholesterol homeostasis. Two fully humanized monoclonal antibodies targeting PCSK9, evolocumab and alirocumab, are available for clinical use. PCSK9 inhibitors reduce LDL-C 30% more than ezetimibe and 60% more than placebo when added to statins. This reduction in LDL-C is accompanied by a decrease in the risk of major cardiovascular and cerebrovascular events.
Source: Journal of Stroke and Cerebrovascular Diseases - August 24, 2021 Category: Neurology Authors: Bayan Moustafa, Fernando D Testai Tags: Review Article Source Type: research
Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis
Clin Ther. 2021 Jun 3:S0149-2918(21)00215-0. doi: 10.1016/j.clinthera.2021.04.019. Online ahead of print.ABSTRACTPURPOSE: The effect of more intensive LDL-C-lowering therapy (ILLT) on long-term cardiovascular outcomes during the early phase of acute coronary syndromes (ACSs) remains uncertain. We aimed to explore the influence of more intensive LDL-C-lowering therapyduring the early disease phase on long-term cardiovascular events among patients with ACSs.METHODS: Randomized controlled trials that focused on the effect of more ILLT during early-phase ACSs on long-term major adverse cardiac events (MACEs) were searched in e...
Source: Clinical Therapeutics - June 7, 2021 Category: Drugs & Pharmacology Authors: Siyao Jin Xiaolu Nie Yuxi Li Jinjie Yuan Yimin Cui Libo Zhao Source Type: research
Bempedoic acid: a cholesterol lowering agent with a novel mechanism of action
Expert Rev Clin Pharmacol. 2021 Mar 11. doi: 10.1080/17512433.2021.1901579. Online ahead of print.ABSTRACTINTRODUCTION: Dyslipidemia is a common condition that increases the risk of heart diseases and stroke. High levels of low-density lipoprotein-cholesterol (LDL-C) is correlated with a higher risk for heart disease. A drug class known as "statins" is the gold standard for LDL-C-lowering, but its use in some patients is limited by its adverse effects of myalgias and myopathies. Use of other LDL-C-lowering agents are frequently limited by cost and degree of efficacy. Additionally, many high-risk atherosclerotic cardiovascu...
Source: Expert Review of Clinical Pharmacology - March 11, 2021 Category: Drugs & Pharmacology Authors: Huyen Nguyen Ikenna Akamnonu Tianrui Yang Source Type: research
Searching for the ideal LDL cholesterol estimating formula
For long, low-density lipoprotein cholesterol (LDL-C) has been considered one of the major therapeutic targets for primary and secondary prevention in cardiovascular (CV) disease. Since more than two decades ago, pivotal trials have demonstrated that LDL-C lowering with statins translates into a log proportional reduction in a vast array of CV events (myocardial infarction, stroke, need for coronary or arterial revascularization), as well as mortality [1]. More recently, similar benefits have been observed with other LDL-C lowering therapies, such as ezetimibe [2] and proprotein covertase subtilisin kexin type 9 (PCSK-9) inhibitors [3].
Source: International Journal of Cardiology - March 9, 2021 Category: Cardiology Authors: Remo Holanda de Mendonca Furtado Tags: Editorial Source Type: research
Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 monoclonal antibodies
Curr Med Chem. 2021 Feb 21. doi: 10.2174/0929867328666210222092628. Online ahead of print.ABSTRACTCardiovascular disease (CVD) remains the primary cause of global morbidity and mortality. CVD includes various life-threatening conditions such as myocardial infarction, stroke and peripheral arterial diseases. In this context, atherosclerosis continues to play the principal role in the pathogenesis of these conditions. Atherosclerosis emanates from a set of modifiable and non-modifiable risk factors that include age, male gender, family history, obesity, smoking, diabetes mellitus and hypertension. Recent evidence classifies ...
Source: Current Medicinal Chemistry - March 3, 2021 Category: Chemistry Authors: Adel Hajj Ali Nour Younis Rola Abdallah Farah Shaer Ali Dakroub Mohammed Ayoub Rabah Iratni Hadi Mohamad Yassine Kazem Zibara Alexander Orekhov Ahmed Fawzy El-Yazbi Ali Eid Source Type: research
